Informations: Ceci n’est pas la version la plus récente du modèle de données. Vous trouverez un aperçu de la version à gauche, sous Versions. Vous trouverez la version la plus actuelle ici.
Informations:
Erreur:
ID
4845
Description
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia see http://clinicaltrials.gov/ct2/show/record/NCT00006045
Lien
http://clinicaltrials.gov/ct2/show/record/NCT00006045
Mots-clés
Versions (5)
- 09/12/2013 09/12/2013 - Martin Dugas
- 25/03/2014 25/03/2014 - Martin Dugas
- 11/04/2014 11/04/2014 - Julian Varghese
- 11/04/2014 11/04/2014 - Julian Varghese
- 13/04/2021 13/04/2021 - Dr. rer. medic Philipp Neuhaus
Téléchargé le
11 avril 2014
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY-NC 3.0 Legacy
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Eligibility NCT00006045 AML
Eligibility AML NCT00006045
- StudyEvent: Eligibility
Similar models
Eligibility AML NCT00006045
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
AML
Item
Histologically proven acute myelogenous leukemia (AML) that may have been primary AML, secondary AML, or preceded by hematologic disorder
boolean
C0023467 (UMLS CUI-1)
except M3
Item
All FAB subtypes except M3 Must meet one of the following three criteria: - First relapse within 1 year after documentation of a previous complete remission (CR) achieved by chemotherapy - Refractory to prior chemotherapy comprised of a minimum of 1 induction course, including cytarabine at a minimum of 500 mg/m2 (e.g., 100 mg/m2/day for 5 days) plus an anthracycline - No high dose cytarabine (no cumulative dose greater than 3 g/m2)
boolean
First relapse
Item
First relapse from a previous CR with subsequent autologous bone marrow transplantation (BMT), only if all of the following criteria are met: - First BMT At least 100 days but less than 1 year posttransplantation - At least 25% cellularity of the bone marrow - Previous BMT included full hematopoietic recovery, defined by all of the following: -- Hemoglobin at least 10 g/dL (without transfusion) -- Platelet count at least 100,000/mm3 (without transfusion) -- Absolute neutrophil count at least 1,500/mm3
boolean
C0699753 (UMLS CUI-1)
C1287267 (UMLS CUI-2)
C0948762 (UMLS CUI-3)
C0019046 (UMLS CUI-4)
C1287267 (UMLS CUI-2)
C0948762 (UMLS CUI-3)
C0019046 (UMLS CUI-4)
No BMT
Item
No transplantation candidates
boolean
C1518422 (UMLS CUI-1)
C0005961 (UMLS CUI-2)
C0005961 (UMLS CUI-2)
Bone marrow blasts
Item
Bone marrow blasts (leukemic cells) greater than 10% No chronic myelogenous leukemia in blast crisis
boolean
C0368761 (UMLS CUI-1)
No CNS leukemia
Item
No active CNS leukemia
boolean
C1518422 (UMLS CUI-1)
C1332884 (UMLS CUI-2)
C1332884 (UMLS CUI-2)
Age
Item
Age: 18 and over
boolean
C0001779 (UMLS CUI-1)
Karnofsky performance status
Item
Karnofsky 50-100%
boolean
C0206065 (UMLS CUI-1)
Bilirubin
Item
Bilirubin less than 2.0 mg/dL (unless related to Gilbert's disease or due to leukemic infiltration)
boolean
C0201913 (UMLS CUI-1)
SGOT, SGPT
Item
SGOT or SGPT no greater than 4 times upper limit of normal (unless related to AML) C1522609
boolean
C0201899 (UMLS CUI-1)
C0201836 (UMLS CUI-2)
C0201836 (UMLS CUI-2)
Serum creatinine
Item
Creatinine less than 2.0 mg/dL (unless related to AML)
boolean
C0201976 (UMLS CUI-1)
No major cardiovascular diseases
Item
Left ventricular function normal No unstable cardiac arrhythmias, unstable angina pectoris, or myocardial infarction within the past 6 months No New York Heart Association class III or IV heart disease No electrocardiogram evidence of active ischemia
boolean
C1518422 (UMLS CUI-1)
C0007222 (UMLS CUI-2)
C0007222 (UMLS CUI-2)
Not pregnant or nursing
Item
Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception during and for 1 month after study negation
boolean
C1518422 (UMLS CUI-1)
C0549206 (UMLS CUI-2)
C0006147 (UMLS CUI-3)
C0549206 (UMLS CUI-2)
C0006147 (UMLS CUI-3)
HIV negative
Item
HIV negative
boolean
C0481430 (UMLS CUI-1)
No other major disease
Item
No other active malignancy requiring therapy No active serious infection that is uncontrolled by antimicrobial therapy Medically stable No significant organ dysfunction
boolean
Biologic therapy
Item
At least 30 days since prior experimental biologic therapy (e.g., interleukin-2) No concurrent biologic therapy, including bone marrow transplantation
boolean
C0005527 (UMLS CUI-1)
Chemotherapy
Item
For first relapse AML with recent or prior chemotherapy: Prior hydroxyurea given as a short course (up to 48 hours) allowed, if needed, to reduce the peripheral leukocyte count Hydroxyurea must be discontinued prior to study For refractory AML with recent or prior chemotherapy: Greater than 2 weeks since prior chemotherapy except hydroxyurea given as above No other concurrent chemotherapy
boolean
C0392920 (UMLS CUI-1)
Radiotherapy
Item
No concurrent radiotherapy
boolean
C0034619 (UMLS CUI-1)
Other
Item
No other concurrent experimental therapy Concurrent therapy for other preexisting diseases allowed
boolean